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Abstract. 1-(Benzoyloxy)urea and its derivatives 
were synthesized by modified Scotten-Bauman reaction 
with adding benzoyl chloride or homologs to hydroxyurea 
in tetrahydrofuran. Structure characterization was conduc-
ted based on ultra-violet (UV-VIS) spectrum, infrared 
(FT-IR), H nucleus magnetic resonance (1H NMR), C nuc-
lear magnetic resonance (13C NMR) and mass spectrometry 
(MS). In silico test to predict anti-cancer activity of 1-
(benzoyloxy)urea and its derivatives in ribonucleotide 
reductase enzyme (PDB: 2EUD) was done using Molegro 
Program. The anti-cancer activity test was performed in 
vitroby using MTT method to HeLa cell lines. In silico test 
result (Rerank Score) was correlated relative to anti-cancer 
activity (log1/IC50).  There was a significant linear rela-
tionship between in vitroand in silico anti-cancer activity. 
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1. Introduction 
In Indonesia cancer is the fifth leading cause of 
death after heart disease, stroke, respiratory disease and 
diarrhea. Nearly six percent or 13.2 million of Indonesian 
people suffer from cancer and need early treatment. 
According to WHO, one person is dying every 11 minutes 
in the world because of cancer, and there is one new 
cancer patient every 3 minutes [1]. Based on the Report of 
National Basic Health Research 2013, the prevalence of 
tumor/cancer in Indonesia is 1.4 % per 1,000 people [2].  
Cancer treatment can be carried out in several 
forms: surgery, radiation photo, immunotherapy, stem cell 
and chemotherapy [3]. Chemotherapy still remains one of 
the alternatives in cancer treatment, whether it can be 
done alone or collectively with other forms of treatment. 
There are some anti-cancer drugs used, including 
hydroxyurea.  
Hydroxyurea was first synthesized in 1869, and its 
effect in slowing down the growth of leukocyte cells was 
first observed in 1928. Its clinical use as an anti-cancer 
compound began in the 1960s [4]. Hydroxyurea is 
antineoplastic that performs an activity to slow down the 
work of ribonucleotide reductase enzyme. The enzyme 
function is to convert ribonucleotide into 
deoxyribonucleotide. If the enzyme’s work slows down, 
DNA biosynthesis will also slow down. The activities of 
hydroxyurea are called cytotoxic and antineoplastic that 
exhibits a special effect on S phase and disturbs cell cycle 
in phases of G2 and S [5]. Hydroxyurea is a derivative of 
urea that is used in myeloproliferative syndrome, chronic 
myelogenous leukemia (CML), polycythemia vera, and 
essential thrombocytosis [6].  
To predict the activity of the compound, in silico 
test is carried out via computer simulation. In silico test is 
the method used to initiate discovery of new medicines 
and improve efficiency in the optimization of the main 
compounds activity [7]. The activity of synthesized 
medicinal compound can be predicted from the energy of 
molecular interaction between a receptor and ligand. The 
interaction energy can be illustrated with rerank score. In 
silico test is administered by docking molecule of the 
potential medicinal compound with the selected receptor. 
Docking is an attempt to streamline ligand that is a small 
molecule into the receptor that is a big protein by 
